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Abstract
Aims To assess theeffectsof 4 monthsof increasedphysical activity on health-relatedquality oflife inoverweight individuals
with Type 2 diabetes mellitus, normal or impaired glucose tolerance.
Methods We included 212 individuals without severe physical or cardiovascular impairments aged 61 (57–64) years, with
BMI of 29 (27.5–32) kg⁄m
2. Numbers are median (25th–75th percentile). Subjects were stratiﬁed based on normal glucose
tolerance(n = 128),impairedglucosetolerance(n = 34)orType 2diabetesmellitus(n = 50).Theywererandomizedintoeither
a control group (n = 125), who maintained unaltered habitual lifestyle, or an exercise intervention group (n = 87), who were
directedtoengageinNordicwalkingwithwalkingpoles,5 hperweekover4 months.Self-reportedphysicalactivityandhealth-
related quality of life was assessed at the time of inclusion and after 4 months.
Results Baseline health-related quality of life of this study cohort was similar to, or better than, an age- and sex-matched
Swedish population sample, for 12 of 13 scales. Quality of sleep and BMI were improved for participants with normal glucose
tolerance after 4 months of Nordic walking, with little or no musculoskeletal pain as compared with control subjects. No
correlation was evident between improved quality of sleep and improved BMI.
Conclusions Quality of sleep improved in the group with normal glucose tolerance following 4 months of Nordic walking.
BMIreductiondidnotaccountforthisimprovement.Nordicwalkingcanbeintroducedinaprimaryhealthcaresettingasalow-
cost mode of exercise that promotes weight loss and improved health satisfaction.
Diabet. Med. 28, 1362–1372 (2011)
Keywords exercise, heath-related quality of life, primary health care, sleep, walking
Abbreviations SDPP, Stockholm Diabetes Prevention Program; SWED-QUAL, Swedish health-related quality of life
questionnaire
Introduction
A sedentary lifestyle has become a major threat to public health
worldwide. Physical inactivity predisposes individuals to obesity
andType 2diabetesmellitusandoftenleadstoprematuredeath.
PeoplediagnosedwithType 2diabetesaretypicallymiddle-aged
or older, with a sedentary lifestyle. Daily exercise has been
considered a cornerstone in the lifestyle management of Type 2
diabetes and numerous studies have provided evidence for
reducedmortalityandriskofcardiovasculardiseaseinphysically
active people, irrespective of the diabetic state [1–4]. Exercise
intervention promotes beneﬁcial outcomes and positively
inﬂuences morbidity and mortality even in middle-aged
participants [5–7]. Moreover, regular walking, combined
with reduced caloric intake, has a diabetes-preventive effect in
individuals with impaired glucose tolerance [8–10].
Promoting a physically active daily life should have high
priority in primary healthcare counselling. A proactive
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approach to reduce premature cardiovascular morbidity and
mortality and to delay, or even prevent, the development of
impaired glucose tolerance and Type 2 diabetes. However, an
older sedentary population with Type 2 diabetes is more
susceptible to painful conditions of the musculoskeletal system
[11]. Introducing physical activity as part of a daily regimen for
thetreatmentofType 2diabetesmustthereforebeinitiatedwith
caution. Moreover, attention should be given to quality-of-life
aspects in assessing the beneﬁts of an exercise programme on an
older, sedentary population with Type 2 diabetes.
The aim of this study was to determine if increasing daily
physical activity, in the form of Nordic walking with walking
poles,wouldinﬂuencehealth-relatedqualityoflifeinoverweight
individuals with normal glucose tolerance, impaired glucose
tolerance or Type 2 diabetes.
Subjects and methods
Patient recruitment
This investigation was a randomized, controlled study.
Recruitment was achieved through newspaper advertisements
andpersonallettersofinvitationto447formerparticipantsinthe
Stockholm Diabetes Prevention Program (SDPP) [12], living in
the catchment area of the primary healthcare centre of
Gustavsberg, a suburb outside Stockholm, Sweden. The study
spanned three consecutive summer seasons (2006–2008) and
occurred between May and September. New participants were
recruited each year. Two hundred and twelve individuals were
included (118 females and 94 males). Ninety participants
were recruited by advertisements and 122 were former SDPP
participants. The participants were stratiﬁed for state of glucose
tolerance (normal, impaired glucose tolerance and Type 2
diabetes) and subsequently randomized to either a control or
exercise-interventiongroup.Eachyear,newentriesintothestudy
were randomized into control or intervention groups. For the
randomization procedure, blinded labels with the participants’
names were drawn from a box and assigned to either the control
or intervention group. Subjects randomized to the control group
were invited to participate in the intervention group the
following year. The subjects who joined the study in both
control (ﬁrst entry) and intervention (second entry) groups are
represented only once in this work, as control subjects, skewing
thecontrol⁄exercisegroupnumbers.Thecontrolgroupconsisted
of 125⁄212 individuals. The intervention group consisted of
87⁄212 individuals. Written informed consent was obtained
from all participants. The study was approved by the Ethics
Committee of Karolinska Institutet, Stockholm.
Biochemistry and anthropometry
At the time of inclusion and after 4 months, an oral glucose
tolerance test was performed. Plasma glucose was ﬁrst
determined in the fasting state, prior to the ingestion of 75 g of
glucose in water solution, and again after 2 h, and calculated as
the mean of two capillary blood samples. We used a portable
HemoCue B-Glucose analyser (A ¨ ngelholm, Sweden) for this
purpose [13]. Glucose tolerance was classiﬁed as either normal
glucose tolerance < 8.9, impaired (impaired glucose tolerance)
8.9–12.1orType 2diabetes‡ 12.2 mmol⁄l,accordingtothe2-h
levelafteroneoralglucosetolerancetest.Ofthe212 subjects,50
were classiﬁed as ‘Type 2 diabetes’, 34 as ‘impaired glucose
tolerance’ and 128 as ‘normal glucose tolerance’. The mean
duration(sd)ofdiabeteswas5(4)yearsforsubjectswithType 2
diabetes. Subjects who were previously diagnosed with diabetes
were classiﬁed as Type 2 diabetes regardless of the oral glucose
tolerance test outcome on inclusion in this study.
Body weight and height were assessed at the time of inclusion
and after 4 months. BMI was calculated by the formula body
weight (kg), divided by height (m) squared. A BMI of 18.5–
24.9 kg⁄m
2was considered normal, 25–29.9 kg⁄m
2overweight
and ‡ 30 kg⁄m
2 obese. Systolic and diastolic blood pressures
weredeterminedintheseatedpositionbytheuseofaSpeidelland
Kellertonometer(Jungingen,Germany).Allmeasurementswere
made in the morning, in conjunction with the oral glucose
tolerance test.
Inclusion criteria
Inclusion criteria were as follows: age 45–69 years, BMI
>2 5k g⁄m
2 and, for people with Type 2 diabetes, HbA1c
between 57 and 78 mmol⁄mol [International Federation of
Clinical Chemistry (IFCC) standard], comparable with 7.4–
9.3% [National Glycohemoglobin Standardization Program
(NGSP)standard].Exclusioncriteriawerephysicalimpairment,
symptoms of angina pectoris (chest pain on physical strain),
atrial ﬁbrillation determined by electrocardiogram systolic or
diastolic blood pressure > 160 or > 100 mmHg, respectively,
and insulin treatment.
Assessment of physical activity and intervention protocol
Exercise in this study was unsupervised. Self-reported exercise
was recorded at baseline and after 4 months. The participants
were asked to estimate their physical activity level during the
6 monthspriorto the study and during study participation using
a visual analogue scale to rank the frequency of physical activity
from 0 mm (none) to 100 mm (intensive daily activity).
The participants in the exercise group were instructed to
increase their weekly level of physical activity by 5 h of Nordic
walking for 4 months. Nordic walking is a unique ﬁtness
techniquethatutilizeswalkingpolestoinvolvetheupperbodyin
the exercise, in addition to providing extra support. Participants
received verbal instructions for Nordic walking by a
physiologist⁄personal trainer. The exercise group participants
wereprovidedwithadiaryandaskedtorecorddateandnumber
of minutes for each bout of Nordic walking. To compare self-
reported physical activity with an objective assessment, 25
participants—11 control subjects and 14 intervention
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hip, for 7 days during waking hours (ActiGraph model GT1M;
ActiGraph, Pensacola, FL, USA). This type of accelerometer
records physical activity as total activity counts per min and min
per day of inactivity, low, moderate or vigorous activity and is
considered a valid and reliable tool for measuring physical
activity in adults [14]. No instructions regarding eating habits or
nutrition were provided and no dietary intervention was
administered. The participants in the control group were
directed to continue their habitual daily activity.
Health-related quality of life assessment
A quality-of-life questionnaire was provided at the time of
inclusionandafter4 months.TheSwedishhealth-relatedquality
of life questionnaire (SWED-QUAL) [15], adapted from the
Medical Outcomes Study [16], was used. Medical Outcomes
Study assessments are generic (as opposed to disease speciﬁc)
health-relatedqualityoflifequestionnairesthatpresentresultsas
a health proﬁle. The 66 items of the SWED-QUAL provide the
basis for 13 scales that represent the following aspects of health-
related quality of life: physical functioning, satisfaction with
physical health, pain, role limitation attributable to physical
health, role limitation attributable to emotional health, positive
affect,negativeaffect,cognitivefunctioning,sleep,generalhealth
perception, family functioning, marital functioning and sexual
functioning. The multi-item scales are set between 0 and 100
points, where 0 indicates the lowest possible score and 100 the
highest. Inter-group differences of the SWED-QUAL results are
expressed in terms of statistical signiﬁcance. Effect size is a
complementary method for identifying minimally important
differences of patient-reported outcomes. The minimally
important difference is deﬁned as the smallest change in a
patient-reported outcome that is perceived by the patient as
beneﬁcial. The effect size is deﬁned by the formula: effect
size = (Mtreatment–Mcomparison)⁄SDpooled, M = ‘mean’ i.e. ‘M
treatment’ = mean value after treatment⁄intervention. ‘M
comparison’ = mean value before treatment⁄intervention. An
effect size of 0.2 is considered small, 0.5 moderate and 0.8 is a
large change [17]. The SWED-QUAL has been used in previous
studies including patients with Type 2 diabetes [18,19].
A random sample of 2500 Swedish men and women, aged 18–
85 years, has previously answered the SWED-QUAL. Health
status and anthropometric data are not known for this Swedish
population sample. The SWED-QUAL results of each study
participant were matched, and compared with, the aggregated
results of all Swedish population sample individuals of the same
age and sex.
Statistical methods
Theoriginalpowercalculation,basedontheassumeddifferences
in SWED-QUAL scales of 0 vs. 5 between the control and
intervention groups, with a = 0.05 and power = 0.8, indicated
that 63 participants would be required in each group. With the
skewed randomization, explained above, a power = 0.8 would
be obtained by 77⁄54 participants. In the group with normal
glucose tolerance, we included 75⁄53 individuals ( = power
0.7957). The study was underpowered for participants with
impaired glucose tolerance and those with Type 2 diabetes.
Stata statistical software (StataCorp., College Station, TX,
USA) was used to calculate differences. The score for each scale
was calculated as the median (25th–75th percentile) of the items
(questions) included in each of the 13 scales. Differences within
and between groups were calculated by non-parametric tests:
Wilcoxon’s signed-rank test for within-group comparisons and
Wilcoxon’s rank-sum test for between-group comparisons. Sex
differences between groups were calculated by v
2-test. P-values
< 0.05 were considered statistically signiﬁcant. Spearman’s rho
was determined for the assessment of correlation.
Results
BaselinedatainTable 1arepresentedseparatelyforparticipants
with normal glucose tolerance, impaired glucose tolerance and
Type 2 diabetes. The 212 participants were 61 (57–64) years of
age, with a BMI of 29 (27.5–32) kg⁄m
2. Numbers are median
(25th–75th percentile). Fifty-three per cent of the study
participants were overweight (BMI 25.0–29.9 kg⁄m
2) and
47% were obese (BMI ‡ 30 kg⁄m
2). ANOVA reﬂected a
disease-state dependency for baseline levels of HbA1c
(P < 0.001), systolic blood pressure (P = 0.019) and BMI
(p = 0.0024). Diastolic blood pressure levels were, however,
similar between groups of varying glucose tolerance (P = 0.85).
The 50 participants with Type 2 diabetes reported baseline
health-related quality of life scores at the same level as the 128
participants with normal glucose tolerance, for all 13 SWED-
QUAL scales, when compared with Wilcoxon’s rank-sum test
(statistics not shown). Of the 50 participants classiﬁed as Type 2
diabetes,45werepreviouslyknowntohaveType 2diabetesand
21 were taking anti-diabetic medication. Of the remaining ﬁve
individuals classiﬁed as Type 2 diabetes, two were again
classiﬁed as Type 2 diabetes according to the oral glucose
tolerance test at the end of the study. Two were classiﬁed as
having impaired glucose tolerance and one as having normal
glucose toleranceaccording to this second oral glucose tolerance
test. Ten participants withdrew from the study prior to the
conclusion. The principle of last-observation-carried-forward
was applied in those cases and their initial results were thus
included in the data analysis.
Followinga4-monthperiodofeithersustained(controlgroup)
or increased physical activity (Nordic walking, 5 h per week),
BMIwasreduced by–1.0 (–1.0 to 0.0)kg⁄m
2in the intervention
group with normal glucose tolerance and by 0.0 (–1.0 to 1.0)
kg⁄m
2 in the control group with normal glucose tolerance
(P = 0.0019). BMI did not change signiﬁcantly in the groups
with impaired glucose tolerance or Type 2 diabetes (Table 2).
Visual analogue scale estimates of physical activity increased
signiﬁcantly in the intervention groups with normal glucose
tolerance and Type 2 diabetes, by 30 (10–40) and 24 (10–40)
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Table 2. The calculated effect sizes were 1.0 and 0.8. Walking
diaries were obtained from 91% of the participants in the
intervention group and 78% of the participants with normal
glucose tolerance reported ‡ 80% (4 h⁄week) of prescribed
Nordic walking. Corresponding ﬁgures for participants with
impaired glucose tolerance and Type 2 diabetes were 67 and
50%, respectively. Median values (25th–75th percentile) of
hours per week of Nordic walking were 4.7 (4.1–5.2), 4.6 (3.7–
6.0) and 3.8 (3.1–4.7) for the groups with normal glucose
tolerance, impaired glucose tolerance and Type 2 diabetes,
respectively. ANOVA did not indicate any signiﬁcant difference
between the three groups (P = 0.1468). Comparison by
Wilcoxon’s rank-sum test showed a signiﬁcant difference
between participants with normal glucose tolerance and those
with Type 2 diabetes (P = 0.0218), whereas comparisons
between participants with normal–impaired glucose tolerance
and impaired glucose tolerance–Type 2 diabetes showed no
signiﬁcant differences in hours of Nordic walking per week
(P = 0.8702 and 0.1557, respectively).
Total counts per min, recorded by accelerometers, were 348
(220–528)forthe control group (n = 11)and 466 (348–623)for
the intervention group (n = 14), P < 0.001, Wilcoxon rank-sum
test. Data are median (25th–75th percentile).
Quality of life was assessed with the SWED-QUAL
questionnaire before and after 4 months of control or exercise
intervention. Results of the intention-to-treat analysis of the
SWED-QUAL are presented in Table 2, parallel with
corresponding data from an age- and sex-matched Swedish
population sample. At baseline, the group with normal glucose
tolerance including both control and intervention participants
scored signiﬁcantly higher for eight SWED-QUAL scales
[physical functioning (effect size = 0.4), satisfaction with
physical functioning (0.4), role limitation because of physical
health (0.2), positive affect (0.2), cognitive functioning (0.2),
sleep (0.2), general health ([0.3) and sexual functioning (0.4)],
compared with the Swedish population sample. For the
remaining ﬁve scales, the baseline scores did not differ between
the group with normal glucose tolerance and the Swedish
population sample. The group with impaired glucose tolerance,
including both control and intervention participants, scored
signiﬁcantly higher than the Swedish population sample for
physicalfunctioning(0.4),cognitivefunctioning(0.3),familylife
(0.6)andsexualfunctioning(0.5).Fortheotherninescales,there
were no signiﬁcant differences between participants with
impaired glucose tolerance and the Swedish population sample.
The group with Type 2 diabetes scored signiﬁcantly higher for
sexual functioning (0.3) than their Swedish population sample
counterparts.
Quality of sleep and general health improved signiﬁcantly in
the normal glucose tolerance intervention group, compared
with the normal glucose tolerance control group; effect size 0.4
and 0.1, respectively. In the Type 2 diabetes intervention
group, satisfaction with physical functioning and sleep
improved signiﬁcantly; effect size 0.7 and 0.5, respectively.
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1368 Diabetic Medicine ª 2011 Diabetes UKCorrelation analysis showed no signiﬁcant relationship
between change of quality of sleep and change of BMI
(Spearman’s rho –0.12).
Discussion
The ﬁndings of this study provide evidence that overweight
Swedish individuals with normal glucose tolerance, impaired
glucose tolerance or Type 2 diabetes report health-related
quality of life at the same level as, or better than, an age- and
sex-matchedSwedishpopulationsample.Theparticipantsinthis
study did not suffer from any severe physical or cardiovascular
impairment that limited daily activity. Moreover, their blood
pressurewaswithin,ornearnormalrangeandglucosemetabolic
controlwaswithintheacceptablerangefortheparticipantswith
Type 2diabetes(Table 1).Otherstudieshavereportedimpaired
health-related quality of life in people with Type 2 diabetes [20].
The most prominent factors that negatively affected health-
related quality of life in people with Type 2 diabetes were
macrovascular disease (coronary heart disease and stroke),
psychiatric disorders (depression) and musculoskeletal disorders.
Intheabsenceofco-morbidityordiabetescomplications,Type 2
diabetesdoesnotdirectlyimpairhealth-relatedqualityoflife.Itis
noteworthy that the participants with normal glucose tolerance
in our study scored signiﬁcantly higher than the Swedish
population sample cohort for eight SWED-QUAL scales,
whereas the participants with impaired glucose tolerance
scored signiﬁcantly higher than the Swedish population sample
cohort for four scales and the participants with Type 2 diabetes
foronescale.Thismightimplythathealth-relatedqualityoflifeis
impaired by a worsened state of glucose tolerance. However, the
numberofparticipantswithimpairedglucosetoleranceandwith
Type 2 diabetes in this study was rather low compared with the
group with normal glucose tolerance. This result should
therefore be interpreted with caution.
Although quality of sleep at baseline was at the same level, or
better,inourstudygroupcomparedwiththeSwedishpopulation
sample, this variable improved signiﬁcantly after 4 months of
increased physical activity, whereas it tended to worsen in the
control group. The control group with Type 2 diabetes reported
a pronounced worsening of quality of sleep. We have no
satisfactory explanation for this. There were no indications of a
worsened state of diabetes during the time of study that might
otherwise have offered an explanation. BMI was signiﬁcantly
lowered in the intervention group, but there was no correlation
betweenimprovedqualityofsleepandloweredBMI.Anincrease
of physical activity may therefore have a positive effect on the
quality of sleep.
AreportonthetreatmentofinsomniainadultSwedishcitizens
has recently been published by the Swedish Council on Health
Technology Assessment [21]. Insomnia, deﬁned as difﬁculty in
fallingasleeporearlyawakeningmorethanthreetimesperweek,
was reported by 24% of study participants. Moreover, 11%
reported impaired daytime quality of life as a result of disturbed
night-time sleep. Furthermore, a questionnaire focusing on
insomnia was randomly distributed to Swedish primary care
physicians. The responding physicians (n = 352) reportedseeing
two or more patients per week who requested care for insomnia,
more than half of whom were over 65 years of age. Medication
for sleeping disorders was prescribed for approximately 8% of
adult Swedish citizens in 2008 and to elderly people, often for
long-term use. There is concern that the persistent use of certain
hypnotic drugs may lead to problems of adverse effects and
addiction over time. Thus, Nordic walking and other modes of
exercise may provide a less costly and safer alternative to
medication as a means of alleviating some sleep disorders. The
Swedish Council on Health Technology Assessment report
concludes that the evidence for physical activity and other
alternative methods for treating insomnia are insufﬁcient and
therefore further research is warranted.
Qualityofsleepappearstobeasensitivemarkerofholisticwell-
being, possibly reﬂecting the inﬂuence of somatic disease and
various factors of psychosocial stress. Individuals with Type 2
diabetes whose medical health deteriorated over 4 years have
showndeterioratingqualityofsleep[22].Astudyofpsychological
distress identiﬁed insomnia as one psychological stress factor
contributing to the increased risk of developing pre-diabetes and
Type 2 diabetes in Swedish middle-aged men, but not in women
[12]. A reduced risk of sleep disorders in men and women who
participated in physical activity at least once a week, and in men
whowalkedatabriskpaceformorethansixblocksdailyhasbeen
reported [23]. Studies measuring sleep physiology in individuals
with or without daily exercise have been contradictory, as
assessed in a meta-analytic review. Total sleep time and
slow-wave sleep seemed to increase as a result of exercise,
whereas rapid eye movement sleep and sleep onset latency was
decreased[24].Theassociationsbetweenshortsleepdurationand
increased prevalence of Type 2 diabetes and hypertension have
been described [25,26]. It has been suggested that the common
mechanism may be an over-secretion of adrenocorticotrophic
hormone and cortisol, and that activation of the hypothalamic–
pituitary-adrenal axis in these patients may play a role [24,25].
Hypothalamic–pituitary-adrenal axis activation is regarded as
an effect of various stress factors, and hypothalamic–
pituitary-adrenal hyperactivity has been suggested to promote
the development of insulin resistance, central obesity,
dyslipidaemia, hypertension and Type 2 diabetes [27].
An association of excess weight and impaired health-related
quality of life has been described [28,29]. The authors provide
evidence that physical aspects of health-related quality of life are
negativelyaffectedbyexcessweightorobesity.Theresultsofour
study do not indicate that overweight per se, in the absence of
other disabling conditions, impairs health-related quality of life.
TheparticipantswithType 2diabetesdidnotreportincreased
pain in comparison with Swedish population sample
counterparts (Table 2). This ﬁnding is highly relevant, as
painful conditions of the musculoskeletal system are more
prevalent in people with Type 2 diabetes than in those without
Type 2diabetes[11].Musculoskeletalpainwasaprimaryreason
for subject withdrawal from a Dutch study of a medical ﬁtness
DIABETICMedicine Original article
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paindidnotincreaseinexerciseparticipantswithnormalglucose
tolerance, impaired glucose tolerance or Type 2 diabetes in our
study. No participant left the study for reasons involving
musculoskeletal pain. Nordic walking may thus be a safe mode
of introductory exercise, even for individuals with Type 2
diabetes.
Limitations of this study
Fourmonths’interventionispotentiallytoobriefformeasurable
effectstooccuronsomeoftheaspectsofhealth-relatedqualityof
life under study. Long-term studies of similar exercise intensity
and frequency are warranted to elucidate whether Nordic
walking may be a sustainable mode of exercise, and whether it
produces a more pronounced effect on health-related quality of
life than in this brief intervention study.
Thedailyphysicalactivityofparticipantsinthisstudy,priorto
entry and during the study, was not uniform or controlled or
matched.Self-reportedlevelofphysicalactivityatbaselinevaried
considerably. This factor may have diminished the perceived
exercise effects on health-related quality of life. The addition of
Nordic walking may not have a substantial effect on quality of
life to a person who was moderately physically active before
inclusioninthisstudy.Infuturestudiesofthiskind,basalexercise
exclusion criteria will be considered.
Exercise was not controlled and self-reporting of daily
exercise, as carried out in this study, is not as accurate as
supervised activities. Moreover, the visual analogue scale,
utilized for estimating the frequency of daily physical activity,
has not been validated as a measure of physical activity. In
addition, some physical exercise normally undertaken may have
been replaced by Nordic walking, thus diminishing the intended
increase of physical activity during the time of study.
The numbers of participants with impaired glucose tolerance
and Type 2 diabetes were too low to allow conclusions of
statistical signiﬁcance for these groups. The results of this study,
indicating lower SWED-QUAL scores for people with impaired
glucose tolerance and Type 2 diabetes, compared with
participants with normal glucose tolerance must therefore be
interpreted with caution.
Thefactthatmorethanhalfofthe participantshadpreviously
been involved in the SDPP could theoretically have created some
bias in our ﬁndings. The SDPP was not, however, an
interventional study on the individual level and comprised no
elements of lifestyle intervention. Moreover, the SWED-QUAL
questionnaire was not used in the SDPP survey. Awareness of
being overweight was an expressed concern and reason for the
majorityofindividualstoparticipateinthisstudy.Itwouldseem
unlikely that the former participation in the SDPP could
somehow inﬂuence the results of this study.
Baseline classiﬁcation of normal glucose tolerance, impaired
glucose tolerance or Type 2 diabetes was based on one oral
glucose tolerance test only. The diagnosis of asymptomatic
diabetes in clinical practice would require the conﬁrmation by a
second oral glucose tolerance test. For the 45 participants with a
diagnosis of Type 2 diabetes established prior to the time of
inclusioninthisstudy,asecondoralglucosetolerancetestwould
be redundant. Five participants were classiﬁed as ‘previously
unknown Type 2 diabetes’ and, for two individuals in this
group, the diagnosis was conﬁrmed by a second oral glucose
tolerance test at the end of the study. The remaining three
individualswereclassiﬁedas‘impairedglucosetolerance’(2)and
‘normal glucose tolerance’ (1) after the second oral glucose
tolerance test.
Strengths of this study
This study was undertaken in a primary care setting. It can serve
as an example of how exercise could be introduced to selected
patients who mightproﬁt from a more physically active lifestyle.
The participants were responsible for their own exercise
schedules and the study did not involve costly supervision of
exercise sessions. The exercise participants received instructions
from a personal trainer for Nordic walking at baseline and one
supportivetelephonecallafter2 monthsfromanassistantnurse.
Although not a very strenuous mode of exercise, Nordic
walking is more strenuous than brisk walking as the use of
walking poles also activates the muscles of the upper limbs. It
may therefore suit people who are unaccustomed to exercising.
Our experience was that Nordic walking did not cause adverse
reactions of musculoskeletal pain.
Three different means of reporting physical activity were
used in this study: visual analogue scales, exercise diaries and
accelerometers. All methods indicated that the intervention
group was more physically active than the control group.
Although the intensity of exercise was not well established, we
can reasonably assume that the self-reported amount of exercise
has been a rather accurate account of actual exercise
performed, based on the subjects who also used accelerometer
reporting.
Future research
The implementation of sustainable, regular exercise habits is a
challenging undertaking. Exercise on prescription is presently
practised in Swedish primaryhealth care,and hasbeen shown to
promote increased self-reported physical exercise and improved
quality of life [31]. Our results imply that a small increment of
regularphysicalactivitydoesnotimpairhealth-relatedqualityof
life. In our study, health-related quality of life tended to improve
following exercise intervention.This experiencecould beused in
clinicaleffortsofmotivatingpatientstoassumeamorephysically
active life, a factor of utmost importance in health counselling of
people with excess weight, disturbed glucose metabolism,
hypertension and other cardiovascular risk factors. Introducing
regularexercisetoindividualsunaccustomedtoexercisetraining
or suffering from cardiovascular disease should be done with
care, taking into account the risks of cardiovascular or
musculoskeletal complications.
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1370 Diabetic Medicine ª 2011 Diabetes UKFuture studies of health-related quality of life in relation to
physical activity should involve supervised exercise and
participants with a somewhat uniform, and low, level of
habitual exercise habits at inclusion. Elucidating whether
people with impaired glucose tolerance or Type 2 diabetes are
less responsive to the effects of regular exercise is clinically
relevant and sufﬁcient numbers of participants with normal
glucose tolerance and Type 2 diabetes should be included.
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